Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 16:23, 16 April 2024

271 bytes added ,  16:23, 16 April 2024
Updated
Line 53: Line 53:  
----<br />
 
----<br />
 
|-
 
|-
−
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
+
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
 +
|4/8/24
 +
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 786: Line 788:  
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 802: Line 804:  
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
 
|Disease
 
|Disease
−
|PENDING
+
|Tracy Tucker, PhD, FCCMG
−
|
+
|4/6/24
−
|
   
|
 
|
 +
|Pending
 
|
 
|
 
|JH_MS
 
|JH_MS
Line 1,471: Line 1,473:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING
+
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
 
| || || || ||Shivani Golem (SG)
 
| || || || ||Shivani Golem (SG)
 
| ||
 
| ||
 
|Monoclonal B-cell Lymphocytosis
 
|Monoclonal B-cell Lymphocytosis
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
 
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
−
|PENDING
+
|PENDING, 4/30/2024
 
|
 
|
 
|Assigned 12/19/2022 with completion date of 1/19/2023
 
|Assigned 12/19/2022 with completion date of 1/19/2023
Line 1,485: Line 1,487:     
Honey Reddi, PhD, Belay Diagnostics
 
Honey Reddi, PhD, Belay Diagnostics
−
| || ||Complete (Shivani, please confirm)|| ||SG|| ||
+
| || ||Complete|| ||SG|| ||
 
|Already converted to 5th edition
 
|Already converted to 5th edition
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
 
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
Line 1,492: Line 1,494:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||PENDING
+
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Hairy Cell Leukemia
 
|Hairy Cell Leukemia
Line 1,500: Line 1,502:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Marginal Zone Lymphoma
 
|Splenic Marginal Zone Lymphoma
Line 1,508: Line 1,510:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||PENDING
+
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
 
| || || || ||SG|| ||
 
| || || || ||SG|| ||
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
 
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
Line 1,518: Line 1,520:  
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|[[HAEM5:Splenic B-cell lymphoma/leukaemia with prominent nucleoli|Splenic B-cell lymphoma/leukaemia with prominent nucleoli]]
 
|Disease
 
|Disease
−
|PENDING
+
|
 
|
 
|
 
|
 
|
Line 2,166: Line 2,168:  
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
 
|Disease
 
|Disease
−
|PENDING
+
|Fei Yang, MD
−
|
   
|
 
|
 
|
 
|
 +
|Pending
 
|
 
|
 
|SK
 
|SK
Line 2,182: Line 2,184:  
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
 
|Disease
 
|Disease
−
|Parastou Tizro (trainee) + Sumi Kitahara
+
|Parastou Tizro, MD (trainee);
 +
Sumire Kitahara, MD
 
|3/17/2024
 
|3/17/2024
 
|
 
|
Line 2,219: Line 2,222:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||PENDING
+
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||
 
| || || || ||SK|| ||
 
| || || || ||SK|| ||
 
|Adult T-cell Leukemia/Lymphoma
 
|Adult T-cell Leukemia/Lymphoma
Line 2,254: Line 2,257:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024
 +
| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,295: Line 2,303:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee); Sumire Kitahara, MD
 +
| || || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,302: Line 2,311:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee),
 +
 
 +
Andrew Siref, MD
 +
|4/12/2024|| ||Pending
 +
| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,396: Line 2,409:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||
+
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
−
| || || || ||SK|| ||
+
|4/1/2024
 +
| ||Pending|| ||SK|| ||
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
 
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
Retrieved from "https://content.ccga.io/index.php/Special:MobileDiff/14396...14409"